Sanofi upgrades 2021 guidance after sales of Dupixent and diabetes products increase

France-based pharmaceutical company Sanofi reported progress on its top line and increasing sales of eczema treatment Dupixent and diabetes products in its quarterly report. The firm is therefore upgrading its guidance for the year.


Sanofi is upgrading its financial guidance for the rest of the year, now expecting growth in earnings per share of around 12 percent excluding currency fluctuations (at Constant Exchange Rates, CER). It previously expected growth of 6-9 percent.

The company reported the new guidance on Thursday when it released its Q2 report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs